** Shares of medtech firm Neuronetics STIM.O down 18.8% at $2.89 post-market as co seeks equity raise
** Malvern, Pennsylvania-based co, which offers its NeuroStar Therapy to treat major depressive disorder, launches stock offering
** Targeted deal size not disclosed
** Co has ~55.65 mln shares outstanding for roughly $200 mln market value and ~27 mln shares of public float, according to LSEG data
** Canaccord Genuity is sole bookrunner for offering
** STIM shares on Thurs rose 8.9% to close at $3.56. YTD, stock up 121%
** Avg rating among 4 analysts is "buy" with $3 median PT - LSEG
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.